Text: H.R.1103 — 116th Congress (2019-2020)All Information (Except Text)

There is one version of the bill.

Text available as:

Shown Here:
Introduced in House (02/07/2019)


116th CONGRESS
1st Session
H. R. 1103


To amend the market name of genetically altered salmon in the United States, and for other purposes.


IN THE HOUSE OF REPRESENTATIVES

February 7, 2019

Mr. Young (for himself, Mr. DeFazio, and Ms. Bonamici) introduced the following bill; which was referred to the Committee on Energy and Commerce


A BILL

To amend the market name of genetically altered salmon in the United States, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Genetically Engineered Salmon Labeling Act”.

SEC. 2. Purposes.

It is the purpose of this Act to—

(1) ensure that consumers in the United States can make informed decisions when purchasing salmon; and

(2) authorize an independent scientific review of—

(A) the possible effects of genetically engineered salmon on wild salmon stocks; and

(B) the Food and Drug Administration’s approval of genetically engineered salmon for human consumption.

SEC. 3. Market name for genetically engineered salmon.

(a) In General.—Notwithstanding any other provision of law, for purposes of applying the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), the acceptable market name of any salmon that is genetically engineered shall include the words “Genetically Engineered” or “GE” prior to the existing acceptable market name.

(b) Definition.—For purposes of this section, salmon is genetically engineered if it has been modified by recombinant DNA (rDNA) techniques, including the entire lineage of salmon that contain the rDNA modification.

SEC. 4. Third-party review of certain salmon approval.

The Secretary of Health and Human Services shall ensure that an independent scientific organization conducts a review of the environmental assessment that was carried out by the Food and Drug Administration in support of an approval of a new animal drug application related to AquAdvantage Salmon, dated November 12, 2015.